The predictive value of TMB in immunotherapy response in renal cancer remains inconclusive.[57,58] Our somatic mutation profile revealed that VHL had the highest frequency in both high- and low-risk groups, while PBRM1 and SETD2 showed substantial differences in mutation frequency between the 2 groups. This evidence concerns the gene SETD2 and renal carcinoma.